Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Pravastatin
- Accession Number
- DB00175 (APRD00328)
- Type
- Small Molecule
- Groups
- Approved
- Description
Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6’-hydroxyl group that does not require in vivo activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.
- Structure
Structure for DB00175 (Pravastatin)
- Synonyms
- (+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
- Pravastatin acid
- Pravastatina
- Pravastatine
- Pravastatinum
- External IDs
- C10AA03
- Product Ingredients
Ingredient UNII CAS InChI Key Pravastatin Sodium 3M8608UQ61 81131-70-6 VWBQYTRBTXKKOG-NJUCWUMRNA-M - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ach-pravastatin Tablet 20 mg Oral Accord Healthcare Limited Not applicable Not applicable Canada 
Ach-pravastatin Tablet 40 mg Oral Accord Healthcare Limited Not applicable Not applicable Canada Ach-pravastatin Tablet 10 mg Oral Accord Healthcare Limited Not applicable Not applicable Canada Act Pravastatin Tablet 20 mg Oral Actavis Pharma Company 2003-12-09 Not applicable Canada Act Pravastatin Tablet 10 mg Oral Actavis Pharma Company 2003-12-09 Not applicable Canada Act Pravastatin Tablet 40 mg Oral Actavis Pharma Company 2003-12-09 Not applicable Canada Auro-pravastatin Tablet 40 mg Oral Auro Pharma Inc Not applicable Not applicable Canada Auro-pravastatin Tablet 10 mg Oral Auro Pharma Inc Not applicable Not applicable Canada Auro-pravastatin Tablet 20 mg Oral Auro Pharma Inc Not applicable Not applicable Canada Ava-pravastatin Tablet 10 mg Oral Avanstra Inc 2011-10-11 2011-12-12 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-pravastatin Tablet 10 mg Oral Apotex Corporation 2001-02-27 Not applicable Canada Apo-pravastatin Tablet 20 mg Oral Apotex Corporation 2001-02-27 Not applicable Canada Apo-pravastatin Tablet 40 mg Oral Apotex Corporation 2001-02-27 Not applicable Canada Pravastatin Tablet 80 mg/1 Oral Ncs Health Care Of Ky, Inc Dba Vangard Labs 2006-10-23 Not applicable US 
Pravastatin Sodium Tablet 80 mg/1 Oral Apotex Corporation 2011-07-18 Not applicable US Pravastatin Sodium Tablet 20 mg/1 Oral A S Medication Solutions 2010-03-30 2017-06-20 US Pravastatin Sodium Tablet 80 mg/1 Oral Amerincan Health Packaging 2016-06-01 Not applicable US Pravastatin Sodium Tablet 10 mg/1 Oral Mylan Pharmaceuticals 2010-05-27 Not applicable US Pravastatin Sodium Tablet 20 mg/1 Oral Av Kare, Inc. 2014-06-17 Not applicable US 
Pravastatin sodium Tablet 20 mg/1 Oral Citron Pharma LLC 2017-02-02 Not applicable US - International/Other Brands
- Elisor / Lipostat / Mevalotin / Pravaselect / Selipran
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Pal-pravastatin-asa Pravastatin Sodium (10 mg) + Acetylsalicylic acid (81 mg) Kit; Tablet; Tablet, delayed release Oral Paladin Labs Inc 2006-01-13 2015-07-31 Canada Pal-pravastatin-asa Pravastatin Sodium (20 mg) + Acetylsalicylic acid (81 mg) Kit; Tablet; Tablet, delayed release Oral Paladin Labs Inc 2006-01-13 2015-07-31 Canada Pal-pravastatin-asa Pravastatin Sodium (40 mg) + Acetylsalicylic acid (81 mg) Kit; Tablet; Tablet, delayed release Oral Paladin Labs Inc 2006-01-13 2015-07-31 Canada - Categories
- Anticholesteremic Agents
- Antimetabolites
- BCRP/ABCG2 Inhibitors
- BCRP/ABCG2 Substrates
- Cardiovascular System
- Combined Inhibitors of CYP3A4 and P-glycoprotein
- Cytochrome P-450 CYP2C8 Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C9 Substrates
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Substrates
- Enzyme Inhibitors
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hypolipidemic Agents
- Lipid Modifying Agents
- Lipid Regulating Agents
- Naphthalenes
- Noxae
- OATP1B1/SLCO1B1 Substrates
- P-glycoprotein/ABCB1 Inhibitors
- P-glycoprotein/ABCB1 Substrates
- Toxic Actions
- UNII
- KXO2KT9N0G
- CAS number
- 81093-37-0
- Weight
- Average: 424.5277
Monoisotopic: 424.246103506 - Chemical Formula
- C23H36O7
- InChI Key
- TUZYXOIXSAXUGO-PZAWKZKUSA-N
- InChI
- InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
- IUPAC Name
- (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
- SMILES
- [H][[email protected]]12[[email protected]](C[[email protected]](O)C=C1C=C[[email protected]](C)[[email protected]@H]2CC[[email protected]@H](O)C[[email protected]@H](O)CC(O)=O)OC(=O)[[email protected]@H](C)CC
Pharmacology
- Indication
For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.
- Structured Indications
- Pharmacodynamics
The primary cause of cardiovascular (CV) disease is atherosclerotic plaque formation and sustained elevation of cholesterol in the blood increases the risk of CV disease. Pravastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. Pravastatin also inhibits hepatic synthesis if VLDL. At therapeutic doses, pravastatin lowers LDL cholesterol by 20-30%, increase high density lipoprotein (HDL) cholesterol by 3-10%, and decrease plasma triglycerides by 19-34%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease.
- Mechanism of action
Pravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated in vivo. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site. Pravastatin sodium produces its lipid-lowering effect in two ways. First, as a consequence of its reversible inhibition of HMG-CoA reductase activity, it effects modest reductions in intracellular pools of cholesterol. This results in an increase in the number of LDL-receptors on cell surfaces and enhanced receptor-mediated catabolism and clearance of circulating LDL. Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL, the LDL precursor.
Target Actions Organism A3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitorHuman - Absorption
Pravastatin is rapidly absorbed with peak plasma levels of the parent compound achieved 1 to 1.5 hours after administration. The average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. These values however, are variable. Food decreases the systemic bioavailability but the lipid-lowering effect is not impacted. When 20 mg of pravastatin is given orally, the pharmacokinetic parameters are as follows: Cmax = 23.3-26.3 ng/mL; AUC = 54.7 to 62.2 ng•hr/mL.
- Volume of distribution
- Not Available
- Protein binding
50% bound to human plasma proteins.
- Metabolism
Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4. Furthermore, the major degradation product is the 3α-hydroxy isomeric metabolite, which has one-tenth to one-fortieth the HMG-CoA reductase inhibitory activity of the parent compound.
- Route of elimination
Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration, 47% of total body clearance was via renal excretion, while 53% was eliminated by non-renal routes.
- Half life
77 hours
- Clearance
- Not Available
- Toxicity
Side effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD50= 12,000 mg/kg (orally in rat)
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Pravastatin Action Pathway Drug action - Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Kinesin-like protein KIF6 --- (C;C) / (C;T) C Allele Effect Directly Studied Patients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose pravastatin. Details 3-hydroxy-3-methylglutaryl-coenzyme A reductase --- (A;T) T Allele Effect Directly Studied Patients with this genotype have a lesser reduction in LDL cholesterol with pravastatin. Details
Interactions
- Drug Interactions
Drug Interaction Drug group Abafungin The risk or severity of adverse effects can be increased when Abafungin is combined with Pravastatin. Investigational Abiraterone The metabolism of Pravastatin can be decreased when combined with Abiraterone. Approved Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Pravastatin. Approved Acenocoumarol Pravastatin may increase the anticoagulant activities of Acenocoumarol. Approved Acetaminophen The serum concentration of Pravastatin can be increased when it is combined with Acetaminophen. Approved Acetazolamide The serum concentration of Pravastatin can be increased when it is combined with Acetazolamide. Approved, Vet Approved Acetylsalicylic acid The serum concentration of Acetylsalicylic acid can be increased when it is combined with Pravastatin. Approved, Vet Approved Acipimox Acipimox may increase the myopathic rhabdomyolysis activities of Pravastatin. Approved Afatinib The serum concentration of Afatinib can be increased when it is combined with Pravastatin. Approved Albaconazole The risk or severity of adverse effects can be increased when Albaconazole is combined with Pravastatin. Investigational Albendazole The serum concentration of Pravastatin can be increased when it is combined with Albendazole. Approved, Vet Approved Aldesleukin The serum concentration of Pravastatin can be increased when it is combined with Aldesleukin. Approved Aldosterone The serum concentration of Pravastatin can be decreased when it is combined with Aldosterone. Experimental Alectinib The serum concentration of Pravastatin can be increased when it is combined with Alectinib. Approved Alfentanil The serum concentration of Pravastatin can be increased when it is combined with Alfentanil. Approved, Illicit Algeldrate The serum concentration of Pravastatin can be decreased when it is combined with Algeldrate. Experimental Alitretinoin The serum concentration of Alitretinoin can be increased when it is combined with Pravastatin. Approved, Investigational Almagate The serum concentration of Pravastatin can be decreased when it is combined with Almagate. Experimental Almasilate The serum concentration of Pravastatin can be decreased when it is combined with Almasilate. Experimental Aloglutamol The serum concentration of Pravastatin can be decreased when it is combined with Aloglutamol. Experimental Alprazolam The serum concentration of Pravastatin can be increased when it is combined with Alprazolam. Approved, Illicit, Investigational Aluminium The serum concentration of Pravastatin can be decreased when it is combined with Aluminium. Approved Aluminium acetoacetate The serum concentration of Pravastatin can be decreased when it is combined with Aluminium acetoacetate. Experimental Aluminium glycinate The serum concentration of Pravastatin can be decreased when it is combined with Aluminium glycinate. Experimental Aluminum hydroxide The serum concentration of Pravastatin can be decreased when it is combined with Aluminum hydroxide. Approved Amantadine The serum concentration of Pravastatin can be increased when it is combined with Amantadine. Approved Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Pravastatin. Approved, Investigational Ambroxol The serum concentration of Pravastatin can be increased when it is combined with Ambroxol. Approved Aminohippuric acid The serum concentration of Pravastatin can be increased when it is combined with Aminohippuric acid. Approved Amiodarone The metabolism of Pravastatin can be decreased when combined with Amiodarone. Approved, Investigational Amitriptyline The serum concentration of Pravastatin can be increased when it is combined with Amitriptyline. Approved Amlodipine The serum concentration of Pravastatin can be increased when it is combined with Amlodipine. Approved Amodiaquine The serum concentration of Amodiaquine can be increased when it is combined with Pravastatin. Approved Amprenavir The serum concentration of Pravastatin can be decreased when it is combined with Amprenavir. Approved Amrinone The risk or severity of adverse effects can be increased when Amrinone is combined with Pravastatin. Approved Amsacrine The serum concentration of Pravastatin can be increased when it is combined with Amsacrine. Approved Anastrozole The serum concentration of Pravastatin can be increased when it is combined with Anastrozole. Approved, Investigational Antipyrine The serum concentration of Pravastatin can be increased when it is combined with Antipyrine. Approved Apixaban The serum concentration of Apixaban can be increased when it is combined with Pravastatin. Approved Aprepitant The serum concentration of Pravastatin can be increased when it is combined with Aprepitant. Approved, Investigational Arsenic trioxide The serum concentration of Arsenic trioxide can be increased when it is combined with Pravastatin. Approved, Investigational Astemizole The serum concentration of Pravastatin can be increased when it is combined with Astemizole. Approved, Withdrawn Atazanavir The metabolism of Pravastatin can be decreased when combined with Atazanavir. Approved, Investigational Atenolol The serum concentration of Pravastatin can be increased when it is combined with Atenolol. Approved Atomoxetine The metabolism of Pravastatin can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Pravastatin is combined with Atorvastatin. Approved Axitinib The serum concentration of Axitinib can be increased when it is combined with Pravastatin. Approved, Investigational Azelastine The serum concentration of Pravastatin can be increased when it is combined with Azelastine. Approved Azelnidipine The risk or severity of adverse effects can be increased when Azelnidipine is combined with Pravastatin. Approved Azimilide The risk or severity of adverse effects can be increased when Azimilide is combined with Pravastatin. Investigational Azithromycin The serum concentration of Pravastatin can be increased when it is combined with Azithromycin. Approved Barnidipine The risk or severity of adverse effects can be increased when Barnidipine is combined with Pravastatin. Approved Belinostat The serum concentration of Belinostat can be increased when it is combined with Pravastatin. Approved, Investigational Bencyclane The risk or severity of adverse effects can be increased when Bencyclane is combined with Pravastatin. Experimental Benidipine The risk or severity of adverse effects can be increased when Benidipine is combined with Pravastatin. Approved Benzocaine The serum concentration of Pravastatin can be increased when it is combined with Benzocaine. Approved Bepridil The serum concentration of Pravastatin can be increased when it is combined with Bepridil. Approved, Withdrawn Betamethasone The serum concentration of Betamethasone can be increased when it is combined with Pravastatin. Approved, Vet Approved Bezafibrate Bezafibrate may increase the myopathic rhabdomyolysis activities of Pravastatin. Approved Bicalutamide The serum concentration of Pravastatin can be increased when it is combined with Bicalutamide. Approved Bifonazole The serum concentration of Pravastatin can be increased when it is combined with Bifonazole. Approved Biperiden The serum concentration of Pravastatin can be increased when it is combined with Biperiden. Approved Bismuth Subcitrate The serum concentration of Pravastatin can be decreased when it is combined with Bismuth Subcitrate. Approved Bismuth subnitrate The serum concentration of Pravastatin can be decreased when it is combined with Bismuth subnitrate. Experimental Boceprevir The serum concentration of Pravastatin can be increased when it is combined with Boceprevir. Withdrawn Bortezomib The metabolism of Pravastatin can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The metabolism of Pravastatin can be increased when combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Pravastatin. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin. Approved Bromocriptine The serum concentration of Pravastatin can be increased when it is combined with Bromocriptine. Approved, Investigational Buprenorphine The serum concentration of Pravastatin can be increased when it is combined with Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The serum concentration of Pravastatin can be increased when it is combined with Buspirone. Approved, Investigational Butoconazole The risk or severity of adverse effects can be increased when Butoconazole is combined with Pravastatin. Approved Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Pravastatin. Approved Cabergoline The serum concentration of Pravastatin can be increased when it is combined with Cabergoline. Approved Caffeine The serum concentration of Pravastatin can be increased when it is combined with Caffeine. Approved Calcium Carbonate The serum concentration of Pravastatin can be decreased when it is combined with Calcium Carbonate. Approved Calcium silicate The serum concentration of Pravastatin can be decreased when it is combined with Calcium silicate. Experimental Camptothecin The serum concentration of Camptothecin can be increased when it is combined with Pravastatin. Experimental Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Pravastatin. Approved Candesartan cilexetil The serum concentration of Pravastatin can be increased when it is combined with Candesartan. Approved Capecitabine The metabolism of Pravastatin can be decreased when combined with Capecitabine. Approved, Investigational Capsaicin The serum concentration of Pravastatin can be increased when it is combined with Capsaicin. Approved Captopril The serum concentration of Pravastatin can be increased when it is combined with Captopril. Approved Carbamazepine The metabolism of Pravastatin can be increased when combined with Carbamazepine. Approved, Investigational Carbomycin The risk or severity of adverse effects can be increased when Carbomycin is combined with Pravastatin. Vet Approved Carboxyamidotriazole The risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Pravastatin. Investigational Carfilzomib The serum concentration of Carfilzomib can be increased when it is combined with Pravastatin. Approved Caroverine The risk or severity of adverse effects can be increased when Caroverine is combined with Pravastatin. Experimental Carvedilol The serum concentration of Pravastatin can be increased when it is combined with Carvedilol. Approved, Investigational Caspofungin The serum concentration of Pravastatin can be increased when it is combined with Caspofungin. Approved Ceritinib The serum concentration of Pravastatin can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Pravastatin. Withdrawn Chloramphenicol The serum concentration of Pravastatin can be increased when it is combined with Chloramphenicol. Approved, Vet Approved Chloroquine The serum concentration of Pravastatin can be increased when it is combined with Chloroquine. Approved, Vet Approved Chlorpromazine The serum concentration of Pravastatin can be increased when it is combined with Chlorpromazine. Approved, Vet Approved Chlorpropamide The serum concentration of Pravastatin can be increased when it is combined with Chlorpropamide. Approved Chlorprothixene The serum concentration of Pravastatin can be increased when it is combined with Chlorprothixene. Approved, Withdrawn Chlorzoxazone The serum concentration of Pravastatin can be increased when it is combined with Chlorzoxazone. Approved Cholecalciferol The metabolism of Pravastatin can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cholesterol The serum concentration of Pravastatin can be increased when it is combined with Cholesterol. Experimental Cholestyramine The serum concentration of Pravastatin can be decreased when it is combined with Cholestyramine. Approved Cholic Acid The serum concentration of Pravastatin can be decreased when it is combined with Cholic Acid. Approved Cilazapril The serum concentration of Pravastatin can be increased when it is combined with Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Pravastatin. Approved Cilostazol The serum concentration of Pravastatin can be increased when it is combined with Cilostazol. Approved Cimetidine The serum concentration of Pravastatin can be decreased when it is combined with Cimetidine. Approved Cinnarizine The risk or severity of adverse effects can be increased when Cinnarizine is combined with Pravastatin. Approved Ciprofibrate The risk or severity of adverse effects can be increased when Ciprofibrate is combined with Pravastatin. Approved Ciprofloxacin The serum concentration of Pravastatin can be increased when it is combined with Ciprofloxacin. Approved, Investigational Cisapride The serum concentration of Pravastatin can be increased when it is combined with Cisapride. Approved, Investigational, Withdrawn Cisplatin The serum concentration of Cisplatin can be increased when it is combined with Pravastatin. Approved Citalopram The serum concentration of Pravastatin can be increased when it is combined with Citalopram. Approved Clarithromycin The serum concentration of Pravastatin can be increased when it is combined with Clarithromycin. Approved Clemastine The metabolism of Pravastatin can be decreased when combined with Clemastine. Approved Clevidipine The risk or severity of adverse effects can be increased when Clevidipine is combined with Pravastatin. Approved Clindamycin The serum concentration of Pravastatin can be increased when it is combined with Clindamycin. Approved, Vet Approved Clobazam The serum concentration of Clobazam can be increased when it is combined with Pravastatin. Approved, Illicit Clofazimine The serum concentration of Pravastatin can be increased when it is combined with Clofazimine. Approved, Investigational Clomifene The serum concentration of Clomifene can be increased when it is combined with Pravastatin. Approved, Investigational Clomipramine The serum concentration of Pravastatin can be increased when it is combined with Clomipramine. Approved, Vet Approved Clonidine The serum concentration of Clonidine can be increased when it is combined with Pravastatin. Approved Clopidogrel The serum concentration of Clopidogrel can be increased when it is combined with Pravastatin. Approved, Nutraceutical Clorindione Pravastatin may increase the anticoagulant activities of Clorindione. Experimental Clotiazepam The serum concentration of Pravastatin can be increased when it is combined with Clotiazepam. Approved, Illicit Clotrimazole The metabolism of Pravastatin can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The serum concentration of Clozapine can be increased when it is combined with Pravastatin. Approved Cobicistat The metabolism of Pravastatin can be decreased when combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Pravastatin. Approved Cocaine The serum concentration of Pravastatin can be increased when it is combined with Cocaine. Approved, Illicit Colchicine Colchicine may increase the myopathic rhabdomyolysis activities of Pravastatin. Approved Colesevelam The serum concentration of Pravastatin can be decreased when it is combined with Colesevelam. Approved Colestipol The serum concentration of Pravastatin can be decreased when it is combined with Colestipol. Approved Colforsin The serum concentration of Pravastatin can be increased when it is combined with Colforsin. Experimental Conivaptan The serum concentration of Pravastatin can be increased when it is combined with Conivaptan. Approved, Investigational Conjugated estrogens The serum concentration of Conjugated estrogens can be increased when it is combined with Pravastatin. Approved Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Pravastatin. Approved Cortisone acetate The serum concentration of Pravastatin can be increased when it is combined with Cortisone acetate. Approved Crisaborole The metabolism of Pravastatin can be decreased when combined with Crisaborole. Approved Crizotinib The metabolism of Pravastatin can be decreased when combined with Crizotinib. Approved Cyclophosphamide The serum concentration of Pravastatin can be increased when it is combined with Cyclophosphamide. Approved, Investigational Cyclosporine The serum concentration of Pravastatin can be increased when it is combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproterone acetate The serum concentration of Pravastatin can be increased when it is combined with Cyproterone acetate. Approved, Investigational Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pravastatin. Approved Dabrafenib The serum concentration of Pravastatin can be decreased when it is combined with Dabrafenib. Approved Daclatasvir The serum concentration of Pravastatin can be increased when it is combined with Daclatasvir. Approved Dactinomycin The serum concentration of Pravastatin can be increased when it is combined with Dactinomycin. Approved Dalfopristin The serum concentration of Pravastatin can be increased when it is combined with Dalfopristin. Approved Danazol The serum concentration of Pravastatin can be increased when it is combined with Danazol. Approved Dapagliflozin The serum concentration of Dapagliflozin can be increased when it is combined with Pravastatin. Approved Daptomycin The risk or severity of adverse effects can be increased when Pravastatin is combined with Daptomycin. Approved, Investigational Darodipine The risk or severity of adverse effects can be increased when Darodipine is combined with Pravastatin. Experimental Darunavir The serum concentration of Pravastatin can be increased when it is combined with Darunavir. Approved Dasatinib The serum concentration of Pravastatin can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin The serum concentration of Pravastatin can be decreased when it is combined with Daunorubicin. Approved Debrisoquin The serum concentration of Debrisoquin can be increased when it is combined with Pravastatin. Approved Deferasirox The serum concentration of Pravastatin can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Pravastatin can be decreased when combined with Delavirdine. Approved Desipramine The serum concentration of Pravastatin can be increased when it is combined with Desipramine. Approved Desloratadine The serum concentration of Pravastatin can be increased when it is combined with Desloratadine. Approved, Investigational Dexamethasone The serum concentration of Pravastatin can be decreased when it is combined with Dexamethasone. Approved, Investigational, Vet Approved Dextromethorphan The serum concentration of Pravastatin can be increased when it is combined with Dextromethorphan. Approved Dextropropoxyphene The serum concentration of Pravastatin can be increased when it is combined with Dextropropoxyphene. Approved, Illicit, Withdrawn Diazepam The serum concentration of Diazepam can be increased when it is combined with Pravastatin. Approved, Illicit, Vet Approved Diclofenac The serum concentration of Pravastatin can be increased when it is combined with Diclofenac. Approved, Vet Approved Dicoumarol Pravastatin may increase the anticoagulant activities of Dicoumarol. Approved Diethylstilbestrol The serum concentration of Diethylstilbestrol can be increased when it is combined with Pravastatin. Approved Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Pravastatin. Approved Digoxin The serum concentration of Pravastatin can be decreased when it is combined with Digoxin. Approved Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Pravastatin. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Pravastatin. Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Pravastatin. Experimental Dihydroergotamine The metabolism of Pravastatin can be decreased when combined with Dihydroergotamine. Approved Dihydrotestosterone The serum concentration of Dihydrotestosterone can be increased when it is combined with Pravastatin. Illicit Diltiazem The metabolism of Pravastatin can be decreased when combined with Diltiazem. Approved Dimethyl sulfoxide The serum concentration of Pravastatin can be increased when it is combined with Dimethyl sulfoxide. Approved, Vet Approved Diphenadione Pravastatin may increase the anticoagulant activities of Diphenadione. Experimental Dipyridamole The serum concentration of Pravastatin can be increased when it is combined with Dipyridamole. Approved Docetaxel The serum concentration of Docetaxel can be increased when it is combined with Pravastatin. Approved, Investigational Domperidone The serum concentration of Domperidone can be increased when it is combined with Pravastatin. Approved, Investigational, Vet Approved Dosulepin The metabolism of Pravastatin can be decreased when combined with Dosulepin. Approved Dotarizine The risk or severity of adverse effects can be increased when Dotarizine is combined with Pravastatin. Investigational Doxazosin The serum concentration of Pravastatin can be increased when it is combined with Doxazosin. Approved Doxepin The serum concentration of Pravastatin can be increased when it is combined with Doxepin. Approved Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Pravastatin. Approved, Investigational Doxorubicin The serum concentration of Pravastatin can be decreased when it is combined with Doxorubicin. Approved, Investigational Doxycycline The metabolism of Pravastatin can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronabinol The serum concentration of Pravastatin can be increased when it is combined with Dronabinol. Approved, Illicit Dronedarone The metabolism of Pravastatin can be decreased when combined with Dronedarone. Approved Econazole The serum concentration of Pravastatin can be increased when it is combined with Econazole. Approved Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Pravastatin. Approved Efavirenz The serum concentration of Pravastatin can be decreased when it is combined with Efavirenz. Approved, Investigational Efinaconazole The risk or severity of adverse effects can be increased when Efinaconazole is combined with Pravastatin. Approved Efonidipine The risk or severity of adverse effects can be increased when Efonidipine is combined with Pravastatin. Approved Elbasvir The serum concentration of Elbasvir can be increased when it is combined with Pravastatin. Approved Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Pravastatin. Approved, Investigational Eltrombopag The serum concentration of Pravastatin can be increased when it is combined with Eltrombopag. Approved Enalapril The serum concentration of Pravastatin can be increased when it is combined with Enalapril. Approved, Vet Approved Enzalutamide The serum concentration of Pravastatin can be decreased when it is combined with Enzalutamide. Approved Eperisone The risk or severity of adverse effects can be increased when Eperisone is combined with Pravastatin. Approved, Investigational Epinastine The serum concentration of Epinastine can be increased when it is combined with Pravastatin. Approved, Investigational Epinephrine The serum concentration of Pravastatin can be increased when it is combined with Epinephrine. Approved, Vet Approved Ergoloid mesylate The serum concentration of Pravastatin can be increased when it is combined with Ergoloid mesylate. Approved Ergonovine The serum concentration of Pravastatin can be increased when it is combined with Ergonovine. Approved Ergotamine The serum concentration of Pravastatin can be increased when it is combined with Ergotamine. Approved Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Pravastatin. Approved, Investigational Erythromycin The serum concentration of Pravastatin can be increased when it is combined with Erythromycin. Approved, Vet Approved Estradiol The serum concentration of Estradiol can be increased when it is combined with Pravastatin. Approved, Investigational, Vet Approved Estramustine The serum concentration of Pravastatin can be increased when it is combined with Estramustine. Approved Estriol The serum concentration of Pravastatin can be decreased when it is combined with Estriol. Approved, Vet Approved Estrone The serum concentration of Pravastatin can be decreased when it is combined with Estrone. Approved Ethanol The serum concentration of Pravastatin can be increased when it is combined with Ethanol. Approved Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be increased when it is combined with Pravastatin. Approved Ethyl biscoumacetate Pravastatin may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etoposide The serum concentration of Pravastatin can be increased when it is combined with Etoposide. Approved Etoricoxib The serum concentration of Pravastatin can be increased when it is combined with Etoricoxib. Approved, Investigational Etravirine The serum concentration of Pravastatin can be decreased when it is combined with Etravirine. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Pravastatin. Approved Ezetimibe The serum concentration of Ezetimibe can be increased when it is combined with Pravastatin. Approved Felodipine The serum concentration of Pravastatin can be increased when it is combined with Felodipine. Approved, Investigational Fendiline The risk or severity of adverse effects can be increased when Fendiline is combined with Pravastatin. Withdrawn Fenofibrate The risk or severity of adverse effects can be increased when Fenofibrate is combined with Pravastatin. Approved Fentanyl The serum concentration of Pravastatin can be increased when it is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fenticonazole The risk or severity of adverse effects can be increased when Fenticonazole is combined with Pravastatin. Experimental Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pravastatin. Approved Fexofenadine The serum concentration of Pravastatin can be increased when it is combined with Fexofenadine. Approved Fidaxomicin The serum concentration of Fidaxomicin can be increased when it is combined with Pravastatin. Approved Floxuridine The metabolism of Pravastatin can be decreased when combined with Floxuridine. Approved Fluconazole The metabolism of Pravastatin can be decreased when combined with Fluconazole. Approved Fluindione Pravastatin may increase the anticoagulant activities of Fluindione. Investigational Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Pravastatin. Approved Fluorouracil The metabolism of Pravastatin can be decreased when combined with Fluorouracil. Approved Fluoxetine The serum concentration of Pravastatin can be increased when it is combined with Fluoxetine. Approved, Vet Approved Flupentixol The serum concentration of Pravastatin can be increased when it is combined with Flupentixol. Approved, Withdrawn Fluphenazine The serum concentration of Pravastatin can be increased when it is combined with Fluphenazine. Approved Flurazepam The serum concentration of Pravastatin can be increased when it is combined with Flurazepam. Approved, Illicit Fluticasone furoate The serum concentration of Fluticasone furoate can be increased when it is combined with Pravastatin. Approved Fluticasone propionate The serum concentration of Pravastatin can be increased when it is combined with Fluticasone propionate. Approved Fluvastatin The metabolism of Pravastatin can be decreased when combined with Fluvastatin. Approved Fluvoxamine The metabolism of Pravastatin can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Pravastatin can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Pravastatin can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Pravastatin can be decreased when it is combined with Fosphenytoin. Approved Fusidic Acid The serum concentration of Pravastatin can be increased when it is combined with Fusidic Acid. Approved Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Pravastatin. Approved, Investigational Gallopamil The risk or severity of adverse effects can be increased when Gallopamil is combined with Pravastatin. Investigational Gefitinib The serum concentration of Gefitinib can be increased when it is combined with Pravastatin. Approved, Investigational Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Pravastatin. Approved Gemfibrozil Gemfibrozil may increase the myopathic rhabdomyolysis activities of Pravastatin. Approved Genistein The serum concentration of Pravastatin can be increased when it is combined with Genistein. Investigational Glecaprevir The serum concentration of Glecaprevir can be increased when it is combined with Pravastatin. Approved Glyburide The serum concentration of Pravastatin can be increased when it is combined with Glyburide. Approved Glycerin The serum concentration of Pravastatin can be increased when it is combined with Glycerin. Approved, Investigational Glycerol Phenylbutyrate The serum concentration of Pravastatin can be increased when it is combined with Glycerol Phenylbutyrate. Approved Gramicidin D The serum concentration of Pravastatin can be increased when it is combined with Gramicidin D. Approved Grazoprevir The serum concentration of Grazoprevir can be increased when it is combined with Pravastatin. Approved Grepafloxacin The serum concentration of Grepafloxacin can be increased when it is combined with Pravastatin. Withdrawn Haloperidol The serum concentration of Pravastatin can be increased when it is combined with Haloperidol. Approved Histamine The serum concentration of Pravastatin can be increased when it is combined with Histamine. Approved, Investigational Hydralazine The serum concentration of Pravastatin can be increased when it is combined with Hydralazine. Approved Hydrocortisone The serum concentration of Pravastatin can be increased when it is combined with Hydrocortisone. Approved, Vet Approved Hydrotalcite The serum concentration of Pravastatin can be decreased when it is combined with Hydrotalcite. Experimental Ibuprofen The serum concentration of Ibuprofen can be increased when it is combined with Pravastatin. Approved Idelalisib The serum concentration of Pravastatin can be increased when it is combined with Idelalisib. Approved Ifosfamide The serum concentration of Pravastatin can be increased when it is combined with Ifosfamide. Approved Iloperidone The serum concentration of Pravastatin can be increased when it is combined with Iloperidone. Approved Imatinib The metabolism of Pravastatin can be decreased when combined with Imatinib. Approved Imipramine The serum concentration of Pravastatin can be increased when it is combined with Imipramine. Approved Indacaterol The serum concentration of Indacaterol can be increased when it is combined with Pravastatin. Approved Indinavir The metabolism of Pravastatin can be decreased when combined with Indinavir. Approved indisulam The serum concentration of Pravastatin can be increased when it is combined with indisulam. Investigational Indomethacin The serum concentration of Pravastatin can be increased when it is combined with Indomethacin. Approved, Investigational Inotuzumab ozogamicin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pravastatin. Approved Irbesartan The metabolism of Pravastatin can be decreased when combined with Irbesartan. Approved, Investigational Irinotecan The serum concentration of Irinotecan can be increased when it is combined with Pravastatin. Approved, Investigational Isavuconazole The risk or severity of adverse effects can be increased when Isavuconazole is combined with Pravastatin. Approved Isavuconazonium The metabolism of Pravastatin can be decreased when combined with Isavuconazonium. Approved, Investigational Isoconazole The risk or severity of adverse effects can be increased when Isoconazole is combined with Pravastatin. Approved Isoniazid The serum concentration of Pravastatin can be increased when it is combined with Isoniazid. Approved Isradipine The metabolism of Pravastatin can be decreased when combined with Isradipine. Approved Itraconazole The serum concentration of Pravastatin can be increased when it is combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Pravastatin can be increased when it is combined with Ivacaftor. Approved Ivermectin The serum concentration of Pravastatin can be increased when it is combined with Ivermectin. Approved, Vet Approved Josamycin The serum concentration of Pravastatin can be increased when it is combined with Josamycin. Approved Ketamine The serum concentration of Pravastatin can be increased when it is combined with Ketamine. Approved, Vet Approved Ketazolam The serum concentration of Ketazolam can be increased when it is combined with Pravastatin. Approved Ketoconazole The metabolism of Pravastatin can be decreased when combined with Ketoconazole. Approved, Investigational Kitasamycin The risk or severity of adverse effects can be increased when Kitasamycin is combined with Pravastatin. Experimental Lacidipine The risk or severity of adverse effects can be increased when Lacidipine is combined with Pravastatin. Approved Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Pravastatin. Approved, Investigational Lamotrigine The serum concentration of Lamotrigine can be increased when it is combined with Pravastatin. Approved, Investigational Lansoprazole The serum concentration of Pravastatin can be increased when it is combined with Lansoprazole. Approved, Investigational Lanthanum carbonate The serum concentration of Lanthanum carbonate can be decreased when it is combined with Pravastatin. Approved Lapatinib The serum concentration of Pravastatin can be increased when it is combined with Lapatinib. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Pravastatin. Approved Leflunomide The metabolism of Pravastatin can be decreased when combined with Leflunomide. Approved, Investigational Lenalidomide The serum concentration of Lenalidomide can be increased when it is combined with Pravastatin. Approved Lenvatinib The serum concentration of Lenvatinib can be increased when it is combined with Pravastatin. Approved Lercanidipine The serum concentration of Pravastatin can be increased when it is combined with Lercanidipine. Approved, Investigational Levetiracetam The serum concentration of Levetiracetam can be increased when it is combined with Pravastatin. Approved, Investigational Levofloxacin The serum concentration of Pravastatin can be increased when it is combined with Levofloxacin. Approved, Investigational Levomilnacipran The serum concentration of Levomilnacipran can be increased when it is combined with Pravastatin. Approved Levosalbutamol The serum concentration of Pravastatin can be increased when it is combined with Levosalbutamol. Approved Levothyroxine The serum concentration of Pravastatin can be decreased when it is combined with Levothyroxine. Approved Lidocaine The serum concentration of Pravastatin can be increased when it is combined with Lidocaine. Approved, Vet Approved Lidoflazine The risk or severity of adverse effects can be increased when Lidoflazine is combined with Pravastatin. Experimental Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Pravastatin. Approved Liothyronine The serum concentration of Pravastatin can be decreased when it is combined with Liothyronine. Approved, Vet Approved Liotrix The serum concentration of Pravastatin can be decreased when it is combined with Liotrix. Approved Lisinopril The serum concentration of Pravastatin can be increased when it is combined with Lisinopril. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Pravastatin. Approved Lobeglitazone The metabolism of Pravastatin can be decreased when combined with Lobeglitazone. Approved Lomitapide The serum concentration of Pravastatin can be increased when it is combined with Lomitapide. Approved Lomustine The serum concentration of Pravastatin can be increased when it is combined with Lomustine. Approved Loperamide The serum concentration of Pravastatin can be increased when it is combined with Loperamide. Approved Lopinavir The metabolism of Pravastatin can be decreased when combined with Lopinavir. Approved Loratadine The serum concentration of Pravastatin can be increased when it is combined with Loratadine. Approved Losartan The serum concentration of Pravastatin can be increased when it is combined with Losartan. Approved Lovastatin The metabolism of Pravastatin can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Pravastatin can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Pravastatin can be decreased when it is combined with Lumacaftor. Approved Lurasidone The serum concentration of Pravastatin can be increased when it is combined with Lurasidone. Approved Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Pravastatin. Illicit, Withdrawn Magaldrate The serum concentration of Pravastatin can be decreased when it is combined with Magaldrate. Withdrawn Magnesium Hydroxide The serum concentration of Pravastatin can be decreased when it is combined with Magnesium Hydroxide. Approved Magnesium oxide The serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide. Approved Magnesium peroxide The serum concentration of Pravastatin can be decreased when it is combined with Magnesium peroxide. Experimental Magnesium silicate The serum concentration of Pravastatin can be decreased when it is combined with Magnesium silicate. Experimental Magnesium Sulfate The risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Pravastatin. Approved, Vet Approved Magnesium Trisilicate The serum concentration of Pravastatin can be decreased when it is combined with Magnesium Trisilicate. Approved Manidipine The metabolism of Pravastatin can be decreased when combined with Manidipine. Approved Mannitol The serum concentration of Mannitol can be increased when it is combined with Pravastatin. Approved, Investigational Maprotiline The serum concentration of Pravastatin can be increased when it is combined with Maprotiline. Approved Mebendazole The serum concentration of Pravastatin can be increased when it is combined with Mebendazole. Approved, Vet Approved Mefloquine The serum concentration of Pravastatin can be increased when it is combined with Mefloquine. Approved Megestrol acetate The serum concentration of Pravastatin can be increased when it is combined with Megestrol acetate. Approved, Vet Approved Meprobamate The serum concentration of Pravastatin can be increased when it is combined with Meprobamate. Approved, Illicit Mequitazine The serum concentration of Pravastatin can be increased when it is combined with Mequitazine. Approved Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Pravastatin. Experimental Methadone The serum concentration of Pravastatin can be increased when it is combined with Methadone. Approved Methazolamide The serum concentration of Pravastatin can be increased when it is combined with Methazolamide. Approved Methimazole The serum concentration of Pravastatin can be increased when it is combined with Methimazole. Approved Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Pravastatin. Approved Methylergometrine The serum concentration of Pravastatin can be increased when it is combined with Methylergometrine. Approved Methylprednisolone The serum concentration of Methylprednisolone can be increased when it is combined with Pravastatin. Approved, Vet Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Pravastatin. Approved Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Pravastatin. Approved, Investigational Metronidazole The serum concentration of Pravastatin can be increased when it is combined with Metronidazole. Approved Metyrapone The serum concentration of Pravastatin can be increased when it is combined with Metyrapone. Approved Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Pravastatin. Experimental Mibefradil The serum concentration of Pravastatin can be increased when it is combined with Mibefradil. Withdrawn Miconazole The serum concentration of Pravastatin can be increased when it is combined with Miconazole. Approved, Investigational, Vet Approved Midazolam The serum concentration of Pravastatin can be decreased when it is combined with Midazolam. Approved, Illicit Midostaurin The metabolism of Pravastatin can be decreased when combined with Midostaurin. Approved Mifepristone The serum concentration of Pravastatin can be increased when it is combined with Mifepristone. Approved, Investigational Mirabegron The serum concentration of Mirabegron can be increased when it is combined with Pravastatin. Approved Mirtazapine The serum concentration of Pravastatin can be increased when it is combined with Mirtazapine. Approved Mitomycin The serum concentration of Pravastatin can be increased when it is combined with Mitomycin. Approved Mitotane The serum concentration of Pravastatin can be decreased when it is combined with Mitotane. Approved Mitoxantrone The serum concentration of Pravastatin can be decreased when it is combined with Mitoxantrone. Approved, Investigational Morphine The serum concentration of Pravastatin can be increased when it is combined with Morphine. Approved, Investigational Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be increased when it is combined with Pravastatin. Approved, Investigational Nadolol The serum concentration of Nadolol can be increased when it is combined with Pravastatin. Approved Naftopidil The risk or severity of adverse effects can be increased when Naftopidil is combined with Pravastatin. Investigational Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Pravastatin. Approved Naloxone The serum concentration of Naloxone can be increased when it is combined with Pravastatin. Approved, Vet Approved Naltrexone The serum concentration of Pravastatin can be increased when it is combined with Naltrexone. Approved, Investigational, Vet Approved Naringenin The serum concentration of Pravastatin can be increased when it is combined with Naringenin. Experimental Nefazodone The metabolism of Pravastatin can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Pravastatin can be decreased when it is combined with Nelfinavir. Approved Neostigmine The serum concentration of Pravastatin can be increased when it is combined with Neostigmine. Approved, Vet Approved Netupitant The serum concentration of Pravastatin can be increased when it is combined with Netupitant. Approved Nevirapine The metabolism of Pravastatin can be increased when combined with Nevirapine. Approved Niacin The risk or severity of adverse effects can be increased when Niacin is combined with Pravastatin. Approved, Investigational, Nutraceutical Nicardipine The metabolism of Pravastatin can be decreased when combined with Nicardipine. Approved Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Pravastatin. Approved Nicotinamide The risk or severity of adverse effects can be increased when Nicotinamide is combined with Pravastatin. Approved Nifedipine The serum concentration of Pravastatin can be decreased when it is combined with Nifedipine. Approved Niguldipine The risk or severity of adverse effects can be increased when Niguldipine is combined with Pravastatin. Experimental Nilotinib The metabolism of Pravastatin can be decreased when combined with Nilotinib. Approved, Investigational Niludipine The risk or severity of adverse effects can be increased when Niludipine is combined with Pravastatin. Experimental Nilvadipine The serum concentration of Pravastatin can be increased when it is combined with Nilvadipine. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Pravastatin. Approved, Withdrawn Nimodipine The risk or severity of adverse effects can be increased when Nimodipine is combined with Pravastatin. Approved Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Pravastatin. Approved Nisoldipine The serum concentration of Pravastatin can be increased when it is combined with Nisoldipine. Approved Nitrazepam The serum concentration of Pravastatin can be increased when it is combined with Nitrazepam. Approved Nitrendipine The serum concentration of Pravastatin can be increased when it is combined with Nitrendipine. Approved Nitric Oxide The serum concentration of Pravastatin can be increased when it is combined with Nitric Oxide. Approved Nizatidine The serum concentration of Nizatidine can be increased when it is combined with Pravastatin. Approved Norethisterone The serum concentration of Pravastatin can be decreased when it is combined with Norethisterone. Approved Norfloxacin The serum concentration of Pravastatin can be increased when it is combined with Norfloxacin. Approved Noscapine The serum concentration of Pravastatin can be increased when it is combined with Noscapine. Investigational Odanacatib The serum concentration of Odanacatib can be increased when it is combined with Pravastatin. Investigational Olanzapine The serum concentration of Olanzapine can be increased when it is combined with Pravastatin. Approved, Investigational Olaparib The metabolism of Pravastatin can be decreased when combined with Olaparib. Approved Oleandomycin The risk or severity of adverse effects can be increased when Oleandomycin is combined with Pravastatin. Vet Approved Ombitasvir The serum concentration of Ombitasvir can be increased when it is combined with Pravastatin. Approved Omeprazole The serum concentration of Pravastatin can be increased when it is combined with Omeprazole. Approved, Investigational, Vet Approved Omoconazole The risk or severity of adverse effects can be increased when Omoconazole is combined with Pravastatin. Experimental Osimertinib The serum concentration of Pravastatin can be increased when it is combined with Osimertinib. Approved Otilonium The risk or severity of adverse effects can be increased when Otilonium is combined with Pravastatin. Experimental Oxiconazole The risk or severity of adverse effects can be increased when Oxiconazole is combined with Pravastatin. Approved Oxybutynin The serum concentration of Pravastatin can be increased when it is combined with Oxybutynin. Approved, Investigational Oxymetholone The serum concentration of Pravastatin can be increased when it is combined with Oxymetholone. Approved, Illicit P-Nitrophenol The serum concentration of Pravastatin can be increased when it is combined with P-Nitrophenol. Experimental Paclitaxel The serum concentration of Pravastatin can be increased when it is combined with Paclitaxel. Approved, Vet Approved Palbociclib The serum concentration of Pravastatin can be increased when it is combined with Palbociclib. Approved Palmitic Acid The serum concentration of Pravastatin can be increased when it is combined with Palmitic Acid. Experimental Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Pravastatin. Approved, Investigational Pantoprazole The serum concentration of Pravastatin can be increased when it is combined with Pantoprazole. Approved Paramethasone The serum concentration of Pravastatin can be increased when it is combined with Paramethasone. Approved Paroxetine The risk or severity of adverse effects can be increased when Pravastatin is combined with Paroxetine. Approved, Investigational Pazopanib Pravastatin may increase the hepatotoxic activities of Pazopanib. Approved Pentobarbital The metabolism of Pravastatin can be increased when combined with Pentobarbital. Approved, Vet Approved Pergolide The serum concentration of Pravastatin can be increased when it is combined with Pergolide. Approved, Vet Approved, Withdrawn Perhexiline The risk or severity of adverse effects can be increased when Perhexiline is combined with Pravastatin. Approved Perindopril The serum concentration of Pravastatin can be increased when it is combined with Perindopril. Approved Phenelzine The serum concentration of Pravastatin can be increased when it is combined with Phenelzine. Approved Phenindione Pravastatin may increase the anticoagulant activities of Phenindione. Approved Phenobarbital The metabolism of Pravastatin can be increased when combined with Phenobarbital. Approved Phenprocoumon Pravastatin may increase the anticoagulant activities of Phenprocoumon. Approved Phenytoin The serum concentration of Pravastatin can be decreased when it is combined with Phenytoin. Approved, Vet Approved Pibrentasvir The serum concentration of Pibrentasvir can be increased when it is combined with Pravastatin. Approved Pilocarpine The serum concentration of Pravastatin can be increased when it is combined with Pilocarpine. Approved Pimozide The serum concentration of Pravastatin can be increased when it is combined with Pimozide. Approved Pinaverium The risk or severity of adverse effects can be increased when Pinaverium is combined with Pravastatin. Approved Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Pravastatin. Approved Platelet Activating Factor The serum concentration of Pravastatin can be decreased when it is combined with Platelet Activating Factor. Experimental Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Pravastatin. Approved Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Pravastatin. Approved Posaconazole The metabolism of Pravastatin can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Prazosin The serum concentration of Pravastatin can be increased when it is combined with Prazosin. Approved Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Pravastatin. Approved, Vet Approved Prednisone The serum concentration of Pravastatin can be increased when it is combined with Prednisone. Approved, Vet Approved Pregabalin The risk or severity of adverse effects can be increased when Pregabalin is combined with Pravastatin. Approved, Illicit, Investigational Prenylamine The risk or severity of adverse effects can be increased when Prenylamine is combined with Pravastatin. Withdrawn Primaquine The serum concentration of Pravastatin can be increased when it is combined with Primaquine. Approved Primidone The metabolism of Pravastatin can be increased when combined with Primidone. Approved, Vet Approved Probenecid The serum concentration of Pravastatin can be increased when it is combined with Probenecid. Approved Progesterone The serum concentration of Pravastatin can be decreased when it is combined with Progesterone. Approved, Vet Approved Promethazine The serum concentration of Pravastatin can be increased when it is combined with Promethazine. Approved Propafenone The serum concentration of Pravastatin can be increased when it is combined with Propafenone. Approved Propofol The serum concentration of Pravastatin can be increased when it is combined with Propofol. Approved, Investigational, Vet Approved Propranolol The serum concentration of Pravastatin can be increased when it is combined with Propranolol. Approved, Investigational Protriptyline The serum concentration of Pravastatin can be increased when it is combined with Protriptyline. Approved Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Pravastatin. Approved Pyrimethamine The metabolism of Pravastatin can be decreased when combined with Pyrimethamine. Approved, Vet Approved Quercetin The serum concentration of Pravastatin can be increased when it is combined with Quercetin. Experimental Quetiapine The serum concentration of Quetiapine can be increased when it is combined with Pravastatin. Approved Quinacrine The serum concentration of Pravastatin can be increased when it is combined with Quinacrine. Approved Quinidine The serum concentration of Pravastatin can be increased when it is combined with Quinidine. Approved Quinine The serum concentration of Pravastatin can be increased when it is combined with Quinine. Approved Quinupristin The serum concentration of Pravastatin can be increased when it is combined with Quinupristin. Approved Rabeprazole The serum concentration of Pravastatin can be increased when it is combined with Rabeprazole. Approved, Investigational Raloxifene The serum concentration of Pravastatin can be increased when it is combined with Raloxifene. Approved, Investigational Raltegravir Raltegravir may increase the myopathic rhabdomyolysis activities of Pravastatin. Approved Ranitidine The serum concentration of Pravastatin can be increased when it is combined with Ranitidine. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Pravastatin. Approved, Investigational Ravuconazole The risk or severity of adverse effects can be increased when Ravuconazole is combined with Pravastatin. Investigational Reboxetine The serum concentration of Pravastatin can be increased when it is combined with Reboxetine. Approved, Investigational Regorafenib The serum concentration of Pravastatin can be increased when it is combined with Regorafenib. Approved Repaglinide The serum concentration of Pravastatin can be increased when it is combined with Repaglinide. Approved, Investigational Reserpine The serum concentration of Pravastatin can be decreased when it is combined with Reserpine. Approved Resveratrol The serum concentration of Pravastatin can be increased when it is combined with Resveratrol. Experimental, Investigational Rifabutin The metabolism of Pravastatin can be increased when combined with Rifabutin. Approved Rifampicin The metabolism of Pravastatin can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Pravastatin can be increased when combined with Rifapentine. Approved Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Pravastatin. Approved, Investigational Rilpivirine The serum concentration of Pravastatin can be increased when it is combined with Rilpivirine. Approved Risedronate The risk or severity of adverse effects can be increased when Risedronate is combined with Pravastatin. Approved, Investigational Risperidone The serum concentration of Risperidone can be increased when it is combined with Pravastatin. Approved, Investigational Ritonavir The metabolism of Pravastatin can be decreased when combined with Ritonavir. Approved, Investigational Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Pravastatin. Approved Rivastigmine The serum concentration of Pravastatin can be increased when it is combined with Rivastigmine. Approved, Investigational Rolapitant The serum concentration of Pravastatin can be increased when it is combined with Rolapitant. Approved Rolitetracycline The serum concentration of Pravastatin can be increased when it is combined with Rolitetracycline. Approved Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Pravastatin. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Pravastatin. Approved Roxithromycin The serum concentration of Pravastatin can be increased when it is combined with Roxithromycin. Approved, Withdrawn Rutin The serum concentration of Pravastatin can be increased when it is combined with Rutin. Experimental Salbutamol The serum concentration of Pravastatin can be increased when it is combined with Salbutamol. Approved, Vet Approved Salicylic acid The serum concentration of Salicylic acid can be increased when it is combined with Pravastatin. Approved, Vet Approved Saquinavir The serum concentration of Pravastatin can be decreased when it is combined with Saquinavir. Approved, Investigational Sarilumab The serum concentration of Pravastatin can be increased when it is combined with Sarilumab. Approved Scopolamine The serum concentration of Pravastatin can be increased when it is combined with Scopolamine. Approved Secobarbital The metabolism of Pravastatin can be increased when combined with Secobarbital. Approved, Vet Approved Selegiline The serum concentration of Pravastatin can be increased when it is combined with Selegiline. Approved, Investigational, Vet Approved Selexipag The serum concentration of Selexipag can be increased when it is combined with Pravastatin. Approved Sertaconazole The risk or severity of adverse effects can be increased when Sertaconazole is combined with Pravastatin. Approved Sertraline The serum concentration of Pravastatin can be increased when it is combined with Sertraline. Approved Sildenafil The metabolism of Pravastatin can be decreased when combined with Sildenafil. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Pravastatin. Approved Siltuximab The serum concentration of Pravastatin can be decreased when it is combined with Siltuximab. Approved Simeprevir The serum concentration of Pravastatin can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Pravastatin can be increased when it is combined with Simvastatin. Approved Sirolimus The serum concentration of Pravastatin can be decreased when it is combined with Sirolimus. Approved, Investigational Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Pravastatin. Approved, Investigational Sitaxentan The serum concentration of Pravastatin can be increased when it is combined with Sitaxentan. Approved, Investigational, Withdrawn Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Pravastatin. Approved Solithromycin The risk or severity of adverse effects can be increased when Solithromycin is combined with Pravastatin. Investigational Sorafenib The serum concentration of Sorafenib can be increased when it is combined with Pravastatin. Approved, Investigational Sparfloxacin The serum concentration of Sparfloxacin can be increased when it is combined with Pravastatin. Approved Sphingosine The serum concentration of Sphingosine can be increased when it is combined with Pravastatin. Experimental Spiramycin The risk or severity of adverse effects can be increased when Spiramycin is combined with Pravastatin. Approved Spironolactone The serum concentration of Pravastatin can be increased when it is combined with Spironolactone. Approved St. John's Wort The metabolism of Pravastatin can be increased when combined with St. John's Wort. Nutraceutical Staurosporine The serum concentration of Pravastatin can be increased when it is combined with Staurosporine. Experimental Stiripentol The serum concentration of Pravastatin can be increased when it is combined with Stiripentol. Approved Streptozocin The serum concentration of Pravastatin can be decreased when it is combined with Streptozocin. Approved Sulconazole The risk or severity of adverse effects can be increased when Sulconazole is combined with Pravastatin. Approved Sulfadiazine The metabolism of Pravastatin can be decreased when combined with Sulfadiazine. Approved, Vet Approved Sulfamethoxazole The metabolism of Pravastatin can be decreased when combined with Sulfamethoxazole. Approved Sulfanilamide The serum concentration of Pravastatin can be increased when it is combined with Sulfanilamide. Approved Sulfinpyrazone The serum concentration of Pravastatin can be increased when it is combined with Sulfinpyrazone. Approved Sulfisoxazole The metabolism of Pravastatin can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sumatriptan The serum concentration of Pravastatin can be increased when it is combined with Sumatriptan. Approved, Investigational Sunitinib The serum concentration of Pravastatin can be increased when it is combined with Sunitinib. Approved, Investigational Tacrine The serum concentration of Pravastatin can be increased when it is combined with Tacrine. Withdrawn Tacrolimus The serum concentration of Pravastatin can be decreased when it is combined with Tacrolimus. Approved, Investigational Tadalafil The serum concentration of Pravastatin can be increased when it is combined with Tadalafil. Approved, Investigational Tamoxifen The serum concentration of Pravastatin can be decreased when it is combined with Tamoxifen. Approved Taurocholic Acid The serum concentration of Pravastatin can be increased when it is combined with Taurocholic Acid. Experimental Technetium Tc-99m sestamibi The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Pravastatin. Approved Telaprevir The serum concentration of Pravastatin can be increased when it is combined with Telaprevir. Withdrawn Telithromycin The serum concentration of Pravastatin can be increased when it is combined with Telithromycin. Approved Telmisartan The serum concentration of Pravastatin can be increased when it is combined with Telmisartan. Approved, Investigational Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Pravastatin. Approved Teniposide The serum concentration of Pravastatin can be increased when it is combined with Teniposide. Approved Terazosin The serum concentration of Pravastatin can be increased when it is combined with Terazosin. Approved Terconazole The risk or severity of adverse effects can be increased when Terconazole is combined with Pravastatin. Approved Terfenadine The serum concentration of Pravastatin can be increased when it is combined with Terfenadine. Withdrawn Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Pravastatin. Experimental Teriflunomide The serum concentration of Pravastatin can be increased when it is combined with Teriflunomide. Approved Terodiline The risk or severity of adverse effects can be increased when Terodiline is combined with Pravastatin. Experimental Tesmilifene The serum concentration of Pravastatin can be decreased when it is combined with Tesmilifene. Investigational Testosterone The serum concentration of Pravastatin can be increased when it is combined with Testosterone. Approved, Investigational Tetracycline The serum concentration of Pravastatin can be increased when it is combined with Tetracycline. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Pravastatin. Investigational Thiopental The serum concentration of Pravastatin can be increased when it is combined with Thiopental. Approved, Vet Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Pravastatin. Withdrawn Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Pravastatin. Approved Ticlopidine The metabolism of Pravastatin can be decreased when combined with Ticlopidine. Approved Timolol The serum concentration of Timolol can be increased when it is combined with Pravastatin. Approved Tioclomarol Pravastatin may increase the anticoagulant activities of Tioclomarol. Experimental Tioconazole The serum concentration of Pravastatin can be increased when it is combined with Tioconazole. Approved Tipranavir The serum concentration of Pravastatin can be increased when it is combined with Tipranavir. Approved, Investigational Tocilizumab The serum concentration of Pravastatin can be decreased when it is combined with Tocilizumab. Approved Tofisopam The serum concentration of Pravastatin can be increased when it is combined with Tofisopam. Approved Tolbutamide The metabolism of Pravastatin can be decreased when combined with Tolbutamide. Approved Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pravastatin. Approved Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Pravastatin. Approved Topiroxostat The metabolism of Pravastatin can be decreased when combined with Topiroxostat. Approved Toremifene The serum concentration of Toremifene can be increased when it is combined with Pravastatin. Approved, Investigational Trabectedin Pravastatin may increase the myopathic rhabdomyolysis activities of Trabectedin. Approved, Investigational Tramadol The serum concentration of Pravastatin can be increased when it is combined with Tramadol. Approved, Investigational Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Pravastatin. Approved, Investigational Tranylcypromine The serum concentration of Pravastatin can be increased when it is combined with Tranylcypromine. Approved Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be increased when it is combined with Pravastatin. Approved Trazodone The serum concentration of Pravastatin can be decreased when it is combined with Trazodone. Approved, Investigational Trifluoperazine The serum concentration of Pravastatin can be increased when it is combined with Trifluoperazine. Approved Triflupromazine The serum concentration of Pravastatin can be increased when it is combined with Triflupromazine. Approved, Vet Approved Trimethoprim The serum concentration of Pravastatin can be decreased when it is combined with Trimethoprim. Approved, Vet Approved Trimipramine The serum concentration of Pravastatin can be increased when it is combined with Trimipramine. Approved Troglitazone The serum concentration of Pravastatin can be increased when it is combined with Troglitazone. Withdrawn Tylosin The risk or severity of adverse effects can be increased when Tylosin is combined with Pravastatin. Vet Approved Ubidecarenone The serum concentration of Ubidecarenone can be increased when it is combined with Pravastatin. Experimental Ulipristal The serum concentration of Ulipristal can be increased when it is combined with Pravastatin. Approved Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Pravastatin. Approved Valproic Acid The metabolism of Pravastatin can be decreased when combined with Valproic Acid. Approved, Investigational Valsartan The metabolism of Pravastatin can be decreased when combined with Valsartan. Approved, Investigational Vecuronium The serum concentration of Vecuronium can be increased when it is combined with Pravastatin. Approved Velpatasvir The serum concentration of Velpatasvir can be increased when it is combined with Pravastatin. Approved Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Pravastatin. Approved Venlafaxine The metabolism of Pravastatin can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Pravastatin can be decreased when combined with Verapamil. Approved Vinblastine The serum concentration of Pravastatin can be decreased when it is combined with Vinblastine. Approved Vincristine The serum concentration of Vincristine can be increased when it is combined with Pravastatin. Approved, Investigational Vincristine The serum concentration of Pravastatin can be decreased when it is combined with Vincristine. Approved, Investigational Vinorelbine The serum concentration of Pravastatin can be increased when it is combined with Vinorelbine. Approved, Investigational Vinpocetine The risk or severity of adverse effects can be increased when Vinpocetine is combined with Pravastatin. Investigational Vismodegib The serum concentration of Vismodegib can be increased when it is combined with Pravastatin. Approved Voriconazole The metabolism of Pravastatin can be decreased when combined with Voriconazole. Approved, Investigational Voxilaprevir The serum concentration of Voxilaprevir can be increased when it is combined with Pravastatin. Approved Warfarin Pravastatin may increase the anticoagulant activities of Warfarin. Approved Xylometazoline The risk or severity of adverse effects can be increased when Xylometazoline is combined with Pravastatin. Approved Zafirlukast The metabolism of Pravastatin can be decreased when combined with Zafirlukast. Approved, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Pravastatin. Approved Zidovudine The serum concentration of Zidovudine can be increased when it is combined with Pravastatin. Approved Zimelidine The serum concentration of Pravastatin can be increased when it is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Pravastatin can be decreased when combined with Ziprasidone. Approved Zucapsaicin The serum concentration of Pravastatin can be increased when it is combined with Zucapsaicin. Approved - Food Interactions
- Avoid alcohol.
- Avoid drastic changes in dietary habit.
- Take without regard to meals.
References
- Synthesis Reference
Kae Jong Chung, Joo Kyung Lee, Joo Woong Park, Dong Jin Seo, Sang Choon Lee, "Method for producing pravastatin precursor, ML-236B." U.S. Patent US6204032, issued October, 1976.
US6204032- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB05022
- KEGG Drug
- D00893
- KEGG Compound
- C01844
- PubChem Compound
- 54687
- PubChem Substance
- 46504851
- ChemSpider
- 49398
- BindingDB
- 20688
- ChEBI
- 63618
- ChEMBL
- CHEMBL1144
- Therapeutic Targets Database
- DAP000550
- PharmGKB
- PA451089
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Pravastatin
- ATC Codes
- C10AA03 — Pravastatin
- C10AA — HMG CoA reductase inhibitors
- C10A — LIPID MODIFYING AGENTS, PLAIN
- C10 — LIPID MODIFYING AGENTS
- C — CARDIOVASCULAR SYSTEM
- C10BX — HMG CoA reductase inhibitors, other combinations
- C10B — LIPID MODIFYING AGENTS, COMBINATIONS
- C10 — LIPID MODIFYING AGENTS
- C — CARDIOVASCULAR SYSTEM
- AHFS Codes
- 24:06.08 — Hmg-coa Reductase Inhibitors
- FDA label
- Download (145 KB)
- MSDS
- Download (44 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Bristol myers squibb
- Apotex corp
- Dr reddys laboratories inc
- Glenmark generics ltd
- Lek pharmaceuticals dd
- Lupin pharmaceuticals inc
- Matrix laboratories ltd
- Mylan pharmaceuticals inc
- Pliva hrvatska doo
- Ranbaxy laboratories ltd
- Teva pharmaceuticals usa inc
- Teva pharmaceuticals usa
- Watson laboratories inc
- Zydus pharmaceuticals usa inc
- Packagers
- Advanced Pharmaceutical Services Inc.
- Amerisource Health Services Corp.
- Apotex Inc.
- A-S Medication Solutions LLC
- Bristol-Myers Squibb Co.
- Bryant Ranch Prepack
- Cadila Healthcare Ltd.
- Cardinal Health
- Cobalt Pharmaceuticals Inc.
- Comprehensive Consultant Services Inc.
- Dept Health Central Pharmacy
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Doctor Reddys Laboratories Ltd.
- E.R. Squibb and Sons LLC
- Glenmark Generics Ltd.
- International Laboratories Inc.
- Kaiser Foundation Hospital
- Lek Pharmaceuticals Inc.
- Lupin Pharmaceuticals Inc.
- Major Pharmaceuticals
- Medvantx Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Neuman Distributors Inc.
- Ohm Laboratories Inc.
- Palmetto Pharmaceuticals Inc.
- Par Pharmaceuticals
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Physicians Total Care Inc.
- Pliva Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Resource Optimization and Innovation LLC
- Sandoz
- Southwood Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Vangard Labs Inc.
- Zydus Pharmaceuticals
- Dosage forms
Form Route Strength Tablet Oral 10 mg Kit; tablet; tablet, delayed release Oral Tablet Oral 80 mg Tablet Oral 20 mg Tablet Oral 40 mg Tablet Oral 80 mg/1 Tablet Oral 10 mg/1 Tablet Oral 20 mg/1 Tablet Oral 40 mg/1 - Prices
Unit description Cost Unit Pravachol 40 mg tablet 6.53USD tablet Pravachol 80 mg tablet 6.53USD tablet Pravastatin sodium 40 mg tablet 4.89USD tablet Pravastatin sodium 80 mg tablet 4.89USD tablet Pravachol 20 mg tablet 4.39USD tablet Pravachol 10 mg tablet 4.38USD tablet Pravastatin sodium 20 mg tablet 3.33USD tablet Pravastatin sodium 10 mg tablet 3.28USD tablet Apo-Pravastatin 40 mg Tablet 1.42USD tablet Co Pravastatin 40 mg Tablet 1.42USD tablet Jamp-Pravastatin 40 mg Tablet 1.42USD tablet Mint-Pravastatin 40 mg Tablet 1.42USD tablet Mylan-Pravastatin 40 mg Tablet 1.42USD tablet Novo-Pravastatin 40 mg Tablet 1.42USD tablet Pms-Pravastatin 40 mg Tablet 1.42USD tablet Pravachol 40 mg Tablet 1.42USD tablet Ran-Pravastatin 40 mg Tablet 1.42USD tablet Ratio-Pravastatin 40 mg Tablet 1.42USD tablet Sandoz Pravastatin 40 mg Tablet 1.42USD tablet Apo-Pravastatin 20 mg Tablet 1.18USD tablet Co Pravastatin 20 mg Tablet 1.18USD tablet Jamp-Pravastatin 20 mg Tablet 1.18USD tablet Mint-Pravastatin 20 mg Tablet 1.18USD tablet Mylan-Pravastatin 20 mg Tablet 1.18USD tablet Novo-Pravastatin 20 mg Tablet 1.18USD tablet Pms-Pravastatin 20 mg Tablet 1.18USD tablet Pravachol 20 mg Tablet 1.18USD tablet Ran-Pravastatin 20 mg Tablet 1.18USD tablet Ratio-Pravastatin 20 mg Tablet 1.18USD tablet Sandoz Pravastatin 20 mg Tablet 1.18USD tablet Apo-Pravastatin 10 mg Tablet 1.0USD tablet Co Pravastatin 10 mg Tablet 1.0USD tablet Jamp-Pravastatin 10 mg Tablet 1.0USD tablet Mint-Pravastatin 10 mg Tablet 1.0USD tablet Mylan-Pravastatin 10 mg Tablet 1.0USD tablet Novo-Pravastatin 10 mg Tablet 1.0USD tablet Pms-Pravastatin 10 mg Tablet 1.0USD tablet Pravachol 10 mg Tablet 1.0USD tablet Ran-Pravastatin 10 mg Tablet 1.0USD tablet Ratio-Pravastatin 10 mg Tablet 1.0USD tablet Sandoz Pravastatin 10 mg Tablet 1.0USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5622985 No 1994-10-22 2014-10-22 US CA1323836 No 1993-11-02 2010-11-02 Canada
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 171.2 - 173°C MSDS water solubility Soluble FDA label logP 0.59 FDA label - Predicted Properties
Property Value Source Water Solubility 0.242 mg/mL ALOGPS logP 2.23 ALOGPS logP 1.65 ChemAxon logS -3.2 ALOGPS pKa (Strongest Acidic) 4.21 ChemAxon pKa (Strongest Basic) -2.7 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 124.29 Å2 ChemAxon Rotatable Bond Count 11 ChemAxon Refractivity 113.6 m3·mol-1 ChemAxon Polarizability 46.56 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as medium-chain hydroxy acids and derivatives. These are hydroxy acids with a 6 to 12 carbon atoms long side chain.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Hydroxy acids and derivatives
- Sub Class
- Medium-chain hydroxy acids and derivatives
- Direct Parent
- Medium-chain hydroxy acids and derivatives
- Alternative Parents
- Fatty alcohols / Medium-chain fatty acids / Hydroxy fatty acids / Fatty acid esters / Branched fatty acids / Beta hydroxy acids and derivatives / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters / Carboxylic acids show 3 more
- Substituents
- Fatty alcohol / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Branched fatty acid / Hydroxy fatty acid / Fatty acid ester / Fatty acyl / Dicarboxylic acid or derivatives / Secondary alcohol show 10 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- statin (semi-synthetic), carboxylic ester, secondary alcohol, 3-hydroxy carboxylic acid, hydroxy monocarboxylic acid, carbobicyclic compound (CHEBI:63618)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Nadph binding
- Specific Function
- Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
- Gene Name
- HMGCR
- Uniprot ID
- P04035
- Uniprot Name
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- Molecular Weight
- 97475.155 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
- Gene Name
- SLCO1B1
- Uniprot ID
- Q9Y6L6
- Uniprot Name
- Solute carrier organic anion transporter family member 1B1
- Molecular Weight
- 76447.99 Da
References
- Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
- Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
- Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
- Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799]
- Sharma P, Holmes VE, Elsby R, Lambert C, Surry D: Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013. [PubMed:19919292]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
- Gene Name
- SLCO2B1
- Uniprot ID
- O94956
- Uniprot Name
- Solute carrier organic anion transporter family member 2B1
- Molecular Weight
- 76709.98 Da
References
- Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ: Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009 Feb;19(2):129-38. doi: 10.1097/FPC.0b013e32831bd98c. [PubMed:19151602]
- Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351]
- Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
- Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
- Gene Name
- SLCO1A2
- Uniprot ID
- P46721
- Uniprot Name
- Solute carrier organic anion transporter family member 1A2
- Molecular Weight
- 74144.105 Da
References
- Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
- Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
- Gene Name
- SLC22A8
- Uniprot ID
- Q8TCC7
- Uniprot Name
- Solute carrier family 22 member 8
- Molecular Weight
- 59855.585 Da
References
- Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
- Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
- Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Organic anion transmembrane transporter activity
- Specific Function
- Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
- Gene Name
- ABCC2
- Uniprot ID
- Q92887
- Uniprot Name
- Canalicular multispecific organic anion transporter 1
- Molecular Weight
- 174205.64 Da
References
- Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
- Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y: Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997 Oct;25(10):1123-9. [PubMed:9321514]
- Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y: Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem. 2002 Feb 22;277(8):6497-503. Epub 2001 Dec 17. [PubMed:11748225]
- Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
- Gene Name
- SLC22A11
- Uniprot ID
- Q9NSA0
- Uniprot Name
- Solute carrier family 22 member 11
- Molecular Weight
- 59970.945 Da
References
- Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- Molecular Weight
- 72313.47 Da
References
- Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043]
- Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
- Gene Name
- SLC22A7
- Uniprot ID
- Q9Y694
- Uniprot Name
- Solute carrier family 22 member 7
- Molecular Weight
- 60025.025 Da
References
- Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Symporter activity
- Specific Function
- Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
- Gene Name
- SLC16A1
- Uniprot ID
- P53985
- Uniprot Name
- Monocarboxylate transporter 1
- Molecular Weight
- 53943.685 Da
References
- Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, Tsuji A: Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res. 1995 Nov;12(11):1727-32. [PubMed:8592677]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Transporter activity
- Specific Function
- Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
- Gene Name
- ABCB11
- Uniprot ID
- O95342
- Uniprot Name
- Bile salt export pump
- Molecular Weight
- 146405.83 Da
References
- Morisawa Y, Takikawa H: Effect of bile acids on the biliary excretion of pravastatin in rats. Hepatol Res. 2009 Jun;39(6):595-600. doi: 10.1111/j.1872-034X.2009.00493.x. Epub 2009 Feb 24. [PubMed:19260999]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
- Gene Name
- SLCO1B3
- Uniprot ID
- Q9NPD5
- Uniprot Name
- Solute carrier organic anion transporter family member 1B3
- Molecular Weight
- 77402.175 Da
References
- Link [Link]
Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13